Athersys Inc. (NASDAQ:ATHX)’s share price rose 3.6% during mid-day trading on Thursday . The company traded as high as $2.04 and last traded at $2.02, with a volume of 353,171 shares. The stock had previously closed at $1.95.

ATHX has been the subject of a number of analyst reports. Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Monday, July 11th. Maxim Group restated a “buy” rating on shares of Athersys in a research report on Sunday, May 8th. Finally, TheStreet upgraded Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The firm’s market capitalization is $170.81 million. The company has a 50 day moving average of $2.15 and a 200-day moving average of $2.12.

Athersys (NASDAQ:ATHX) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.32 million. Athersys’s quarterly revenue was up 200.0% compared to the same quarter last year. Equities analysts forecast that Athersys Inc. will post ($0.22) EPS for the current fiscal year.

In other news, COO William Lehmann, Jr. sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $2.17, for a total value of $54,250.00. Following the completion of the transaction, the chief operating officer now directly owns 279,017 shares in the company, valued at approximately $605,466.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.